Research of the OHSU Pituitary Unit Faculty
SOM230 Therapy for Patients with Cushing's Disease
Patients with active Cushing's disease (Cushing's syndrome caused
by an ACTH producing pituitary tumor) who have urine free cortisols
more than 2x the upper limit of normal and are age 18 or greater
will be eligible to be screened for this study. Qualifying patients
will receive SOM230 (a new drug that effects all five somatostatin
receptors) for a 16-day period to see if it effectively treats Cushing's
disease. Urine free cortisols (as well as other tests) will be assessed
before and after drug treatment. All expenses will be paid to the
patients including a stipend for participating. Dr. Maria Fleseriu
is the principal investigator at OHSU. Interested patients should
call Chris at 503.494.6576
Growth Hormone and Testosterone Therapy for Panhypopituitary Women
Women who have lost all pituitary function age 18-55 will qualify.
Growth Hormone (GH) will be given free of change for 24 months and
testosterone in a female dose for 6 months. The growth hormone portion
of the study is not placebo, but the testosterone part is. Patients
will begin an appropriate dose of growth hormone regulated by an
experienced pituitary physician. Part of the study is conducted
at UCLA in Los Angeles, patients travel there twice. All expenses
will be paid to the patients including a stipend for participating.
Dr. David Cook is the principal investigator at OHSU. Interested
patients call Elease at 503.494.1517
The purpose of this study is to compare the efficacy of pasireotide
LAR vs. octreotide LAR in the treatment of acromegaly. Men and women
18 years and older who have been diagnosed with active acromegaly
and who are:
- medical treatment naïve after first surgery or
- de-novo patients who present with a visible adenoma on MRI and
who refuse pituitary surgery or for whom pituitary surgery is
not indicated.
More information available at OHSU
Study Participation.
|
